New targets in inflammatory bowel disease therapy: 2021.

Published on Jul 1, 2021in Current Opinion in Gastroenterology3.225
· DOI :10.1097/MOG.0000000000000740
Nathaniel A Cohen (U of C: University of Chicago), David T. Rubin91
Estimated H-index: 91
Source
Abstract
PURPOSE OF REVIEW In the rapidly progressing world of inflammatory bowel disease, this review discusses and summarizes new drug targets and results from major clinical trials in order to provide an update to physicians treating patients with inflammatory bowel diseases (IBD). RECENT FINDINGS Multiple new mechanisms in the treatment of IBD are being developed and many are showing promising results in both ulcerative colitis and Crohn's disease patients. In addition to efficacy, some of these treatments may provide safety benefits over existing therapies. SUMMARY The IBD physicians' therapeutic armamentarium is rapidly expanding and keeping abreast of these developments is required in order to provide patients with optimized individualized care.
References0
Newest
#1Matthew R. HennH-Index: 43
#2Edward J. O’BrienH-Index: 17
Last. Michele TrucksisH-Index: 4
view all 21 authors...
Abstract Background & Aims Firmicutes bacteria produce metabolites that maintain the intestinal barrier and mucosal immunity. Firmicutes are reduced in the intestinal microbiota of patients with ulcerative colitis (UC). In a phase 1b trial of patients with UC, we evaluated the safety and efficacy of SER-287, an oral formulation of Firmicutes spores, and the effects of vancomycin preconditioning on expansion (engraftment) of SER-287 species in the colon. Methods We conducted a double-blind trial ...
5 CitationsSource
#1William J. Sandborn (UCSD: University of California, San Diego)H-Index: 182
#2Deanna D NguyenH-Index: 1
Last. Julián PanésH-Index: 94
view all 18 authors...
BACKGROUND AND AIMS: Oral systemic pan-Janus kinase (JAK) inhibition is effective for ulcerative colitis (UC) but limited by toxicities. We describe preclinical to clinical translation of TD-1473-an oral gut-selective pan-JAK inhibitor-from in vitro characterization through a Phase 1b study in patients with UC. METHODS: TD-1473 JAK inhibition potency was evaluated in vitro; plasma pharmacokinetics, safety, and efficacy were assessed in mice. In the first-time-in-human study, plasma pharmacokinet...
11 CitationsSource
#1William J. Sandborn (UCSD: University of California, San Diego)H-Index: 182
#2Brian G. Feagan (UWO: University of Western Ontario)H-Index: 115
Last. Julián PanésH-Index: 94
view all 22 authors...
Abstract Background & Aims We evaluated the efficacy and safety of upadacitinib, an oral selective Janus kinase 1 inhibitor, in a randomized trial of patients with Crohn’s disease (CD). Methods We performed a double-blind, phase 2 trial in adults with moderate to severe CD and inadequate response or intolerance to immunosuppressants or tumor necrosis factor antagonists. Patients were randomly assigned (1:1:1:1:1:1) to groups given placebo or 3 mg, 6 mg, 12 mg, or 24 mg upadacitinib twice daily, ...
26 CitationsSource
#1William J. Sandborn (UCSD: University of California, San Diego)H-Index: 182
#2Subrata Ghosh (NIHR: National Institute for Health Research)H-Index: 85
Last. Peter D.R. Higgins (UM: University of Michigan)H-Index: 67
view all 12 authors...
ABSTRACT Background & Aims We evaluated the efficacy and safety of upadacitinib, an oral selective inhibitor of Janus kinase 1, as induction therapy for ulcerative colitis (UC). Methods We performed a multicenter, double-blind, phase 2b study of 250 adults with moderately to severely active UC and an inadequate response, loss of response, or intolerance to corticosteroids, immunosuppressive agents, and/or biologic therapies. Patients were randomly assigned to groups that received placebo or indu...
21 CitationsSource
#1Allison LuoH-Index: 10
#2Robert LesterH-Index: 1
Last. William J. SandbornH-Index: 182
view all 8 authors...
Source
#1Rish K. PaiH-Index: 30
#2James B. CanavanH-Index: 12
Last. William J. SandbornH-Index: 182
view all 10 authors...
2 CitationsSource
#1Andres YarurH-Index: 19
#2Michael V. ChioreanH-Index: 11
Last. William J. SandbornH-Index: 182
view all 11 authors...
Source
#1Liyuan Xiang (Nanjing Medical University)H-Index: 5
#2Xiao Ding (Nanjing Medical University)H-Index: 6
Last. Faming ZhangH-Index: 26
view all 9 authors...
The efficacy of faecal microbiota transplantation (FMT) in Crohn's disease (CD) remains unclear due to lack of data. This study aimed to assess the value of FMT in treating CD-related clinical targets. The use of FMT for CD as a registered trial (NCT01793831) was performed between October 2012 and December 2017. Seven therapeutic targets included abdominal pain, diarrhoea, hematochezia, fever, steroid-dependence, enterocutaneous fistula and active perianal fistula. Each target was recorded as 1 ...
5 CitationsSource
#1Inyoung HwangH-Index: 1
#2Sang Won LeeH-Index: 17
Last. Kyung-Sang YuH-Index: 29
view all 5 authors...
Source
#1William J. Sandborn (UCSD: University of California, San Diego)H-Index: 182
#2Marc Ferrante (Universitaire Ziekenhuizen Leuven)H-Index: 9
Last. Geert R. D'Haens (UvA: University of Amsterdam)H-Index: 76
view all 14 authors...
Abstract Background & Aims Interleukin 23 (IL23) contributes to pathogenesis of ulcerative colitis (UC). We investigated the effects of mirikizumab, a monoclonal antibody against the p19 subunit of IL23, in a phase 2 study of patients with UC. Methods We performed a trial of the efficacy and safety of mirikizumab in patients with moderate to severely active UC, enrolling patients from 14 countries from January 2016 through September 2017. Patients were randomly assigned to groups given intraveno...
33 CitationsSource
Cited By0
Newest